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This article has been corrected: Due to errors in image preparation, two panels in Figures 4 and 5 were accidentally 
duplicated. The corrected Figures 4 and 5 are shown below. The authors declare that these corrections do not change the 
results or conclusions of this paper.
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Figure 4: Prototype of tumors upon sacrifice, formed in non-diabetic and diabetic mice treated with rapamycin, metformin and 
their combination with probiotics. Note the difference in tumor size in the different groups; animals from groups 4B and 8B treated with 
rapamycin and metformin in combination with probiotics had significantly smaller tumor size when compared to groups treated with Met 
alone, rapamycin alone or untreated animals.
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Figure 5: H&E histological examination of the representative HCT116 xenograft tumors in the different groups. (A) a 200x 
magnification of a tumor section in non-diabetic, injected with HCT116 cells and non-treated showing high cellular density, vascularization 
(black arrows), and tumor cells surrounded by a remarkable infiltration of inflammatory cells (red arrows). (B) a 20x magnification 
showing some necrotic areas in the tumor (Black arrows) in non-diabetics, rapamycin alone (G2) (C) 20x magnification showing some 
necrotic areas in the tumor (Black arrows) in non-diabetics metformin alone (D) 4x and (E) 200x magnification show large necrotic areas 
in the tumor section with low cell density (black arrows) in non-diabetics treated with metformin combined to rapamycin. (F) 40x and 
(G) 200x magnification showing necrotic areas (Black arrows), along with a lower density of the cells in diabetic treated with metformin, 
rapamycin combined with probiotics (G4B). Note that all tumors from 5 animals in the same group showed similar morphology. (H) Whole 
view of a well-demarcated tumor formed with a scanty fibrous capsule and a moderately produced connective tissue in diabetic non-treated 
animals. Note the sheet-like proliferation showing growth of solid tumor cells. (I) 200x magnification of the tumor section in G5, note the 
high density of the cells along with increase in vascularity (black arrows) (J) 200x magnification of a tumor section, showing a moderate 
cells density along with an increase in vascularity (black arrows) in diabetics treated with rapamycin alone (G6). (K) 200x magnification 
of a tumor section, note the moderate density of the cells in diabetics treated with metformin alone (G7). (L) 200x magnification of tumor 
section from diabetic mice treated with metformin and rapamycin showing a lesser density of the cells than either alone (M) 200x and 
(N) 20x magnification of tumor section from diabetic mice with the triple therapy showing necrotic areas (Black arrows), along with a 
significant decrease in cellular density.
